New: theragenomicsAll contenthive-129948hive-196917krsteemhive-183959zzanhive-180932hive-185836photographyuncommonlabhive-166405bitcoinhive-188619hive-144064hive-150122hive-145157hive-183397hive-184714lifehive-109690hive-139150hive-124908hive-153970krsuccesshive-193186TrendingNewHotLikersgut50 (25)in theragenomics • 5 years agoFebuxostat (Uloric) and its problem with cardiovascular mortalityDespite drug safety problems of cardiovascular mortality with Febuxostat (Uloric), the benefits might still be seen to outweigh risks for selected gout patients. This notion may become more and more…gut50 (25)in theragenomics • 5 years agoGrossesse et risques de malformations: Il n'y a pas seulement le valproatemay 01, 2019 - En France, l’Agence nationale de sécurité du médicament et des produits de santé (ANSM) viens de publier une analyse des données disponibles sur le risque de malformations et de…gut50 (25)in theragenomics • 5 years agoLemtrada: Deleterious unwanted effects in some multiple sclerosis patientsLemtrada: Deleterious unwanted effects in some multiple sclerosis patients Alemtuzumab (Lemtrada) is used in the treatment of multiple sclerosis (MS). Moreover, Alemtuzumab, under the Tradenames…